Research dossier

PT-141 — melanocortin MC4R selectivity dossier

A metabolite of Melanotan II, where the loss of one group changes the selectivity.

6 min read · Purpeptide Research Desk ·

Translated from the French original, which remains the reference version: lire en français →

PT-141 — research dossier illustration

Molecular identity

ParameterValue
CAS number189691-06-3
Molar mass1025.18 g/mol
Molecular formulaC₅₀H₆₈N₁₄O₁₀
Sequence / natureAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Purity≥99%
AppearanceWhite lyophilised powder

The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.

Research context

The metabolite-to-parent relationship between this compound and Melanotan II makes it a case study in how a minimal terminal modification influences receptor selectivity. It is a frequently cited example in structure-activity relationships.

Mechanism studied

PT-141, called bremelanotide in the literature, is a cyclic heptapeptide. Its structural relationship to Melanotan II is direct: it is the deamidated metabolite, that is, the form in which the C-terminal amide group has been hydrolysed to a carboxylic acid.

That apparently minor difference changes the selectivity profile between melanocortin receptor subtypes. The literature describes PT-141 as showing relatively greater activity at MC4R, while Melanotan II retains substantial activity at MC1R.

The melanocortin receptors are Gs-coupled; their activation is measured in culture by cAMP accumulation. The family comprises five subtypes (MC1R to MC5R) with distinct tissue distributions, and any selectivity assay must include them — a compound active at MC4R alone and one active across the whole family producing very different observations.

Cyclisation by a lactam bridge constrains the conformation and is a structural element decisive for affinity.

In-vitro literature

The published assays rest on cell lines separately expressing each of the recombinant human subtypes, with cAMP measurement. Complete selectivity panels are the methodological norm in this field.

Bibliographic entry points

These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.

Distinguishing this compound from its analogues

The deamidated metabolite of Melanotan II. The two compounds are frequently confused although their selectivity profiles differ.

The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.

Methodological limits

Relative selectivity between melanocortin subtypes is not absolute: it is expressed as affinity ratios rather than all-or-nothing. A complete MC1R–MC5R panel is needed to interpret a result. The 1 Da difference from the amidated form requires sufficient mass resolution.

These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.

Analytical parameters

A peptide cyclised by a lactam bridge. The integrity of the ring and the state of the C-terminus must be confirmed by mass spectrometry, the amidated and acid forms differing by about 1 Da.

ParameterValue
StorageStore at −20 °C, protected from light
SolubilitySoluble in bacteriostatic water (BAC)
StabilityStable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C
Control methodsRP-HPLC · MS · NMR

Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.

Resulting concentrations

The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.

Format1 ml2 ml3 ml
10mg10.00 mg/ml5.00 mg/ml3.33 mg/ml

These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.

Protocol design

Three points govern the validity of an assay using this material, whatever the question being asked.

The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.

The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.

The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.

Lot verification

The following formats are covered by a Janoshik Analytical report, readable from the product page:

  • 10mg — lot report available
FormatLot reportAvailability
10mgCoveredIn stock

The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.

Frequently asked questions

How does this product arrive?

As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.

Which solvent should be used for reconstitution?

Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.

How long does the material remain stable?

The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.

Does the analysis report correspond exactly to my vial?

The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.

Can this product be used on humans or animals?

No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.

See also: Melanotan II or PT-141: the comparison

Dossiers in the same category

Related dossiers

All research dossiers → · Catalogue → · Glossary →